PF-07921585 is under clinical development by Pfizer and currently in Phase I for Metastatic Colorectal Cancer.
Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback